{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:04:22Z","timestamp":1791425062217,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01849-0","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:01:07Z","timestamp":1783591267000},"page":"4241-4248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["American Academy of Dermatology 2026 Annual Meeting: Updates in Hidradenitis Suppurativa Medical Management"],"prefix":"10.1007","volume":"16","author":[{"given":"Kenan","family":"Kherallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"9","key":"1849_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s13555-025-01487-y","volume":"15","author":"A Garg","year":"2025","unstructured":"Garg A, Hsiao J, Porter ML, Shi V. Current treatments and future directions for hidradenitis suppurativa: a narrative review of completed and ongoing phase 3 clinical trials of biologic therapies. Dermatol Ther. 2025;15(9):2361\u201377. https:\/\/doi.org\/10.1007\/s13555-025-01487-y.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1849_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40257-026-01011-8","volume":"27","author":"A Martorell","year":"2026","unstructured":"Martorell A, Ingram JR, Sayed CJ, et al. Defining moderate disease and progression in hidradenitis suppurativa: an expert framework to unlock the window of opportunity for prompt treatment. Am J Clin Dermatol. 2026;27(2):217\u201326. https:\/\/doi.org\/10.1007\/s40257-026-01011-8.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1849_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","volume":"69","author":"BE Rumberger","year":"2020","unstructured":"Rumberger BE, Boarder EL, Owens SL, Howell MD. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res. 2020;69(10):967\u201373. https:\/\/doi.org\/10.1007\/s00011-020-01381-7.","journal-title":"Inflamm Res"},{"issue":"5","key":"1849_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051351","volume":"15","author":"YC Tsai","year":"2023","unstructured":"Tsai YC, Hung CY, Tsai TF. Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis. Pharmaceutics. 2023;15(5):1351. https:\/\/doi.org\/10.3390\/pharmaceutics15051351.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1849_CR5","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.14617170","volume":"63","author":"PD Elizalde-Hern\u00e1ndez","year":"2025","unstructured":"Elizalde-Hern\u00e1ndez PD, Solis-Gonz\u00e1lez AJ, M\u00e9ndez-Flores FL, Estrada-Aguilar L. Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy. Rev Med Inst Mex Seguro Soc. 2025;63(2):e6596. https:\/\/doi.org\/10.5281\/zenodo.14617170.","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"1849_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2024.12.008","volume":"56","author":"Z Islam","year":"2025","unstructured":"Islam Z, Choi S, Wang L, Andriano TM, Campton K. Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa. JAAD Case Rep. 2025;56:74\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.008.","journal-title":"JAAD Case Rep"},{"key":"1849_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jdcr.2025.10.066","volume":"67","author":"K Kherallah","year":"2026","unstructured":"Kherallah K, Chung CS, Gillenwater J, et al. Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: a case report. JAAD Case Rep. 2026;67:155\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.066.","journal-title":"JAAD Case Rep"},{"key":"1849_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01601-0","author":"K Kherallah","year":"2025","unstructured":"Kherallah K, Chung CS, Ghanshani R, et al. Dual targeted therapy for hidradenitis suppurativa: a narrative review. Dermatol Ther. 2025. https:\/\/doi.org\/10.1007\/s13555-025-01601-0.","journal-title":"Dermatol Ther"},{"key":"1849_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1760206","volume":"17","author":"SX Chen","year":"2026","unstructured":"Chen SX, de O Wafae BG, Look-Why S, et al. Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study. Front Immunol. 2026;17:1760206. https:\/\/doi.org\/10.3389\/fimmu.2026.1760206.","journal-title":"Front Immunol"},{"issue":"10","key":"1849_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0333010","volume":"20","author":"EJ Ma","year":"2025","unstructured":"Ma EJ, Roberts AM, Chou P, et al. Chronic companions: an updated national cross-sectional study of metabolic syndrome comorbidities in outpatient visits for hidradenitis suppurativa. PLoS ONE. 2025;20(10):e0333010. https:\/\/doi.org\/10.1371\/journal.pone.0333010.","journal-title":"PLoS ONE"},{"key":"1849_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70191","author":"Z Islam","year":"2026","unstructured":"Islam Z, Karpoff K, Alicea DS, et al. Glucagon-like peptide-1 receptor agonists are associated with reduced disease severity and pain in hidradenitis suppurativa: a retrospective study. Int J Dermatol. 2026. https:\/\/doi.org\/10.1111\/ijd.70191.","journal-title":"Int J Dermatol"},{"issue":"21","key":"1849_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292. https:\/\/doi.org\/10.3390\/jcm13216292.","journal-title":"J Clin Med"},{"issue":"4","key":"1849_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.jaad.2025.12.092","volume":"94","author":"E Kasheri","year":"2026","unstructured":"Kasheri E, Smith J, Min MS. Glucagon-like peptide-1 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: a TriNetX retrospective analysis. J Am Acad Dermatol. 2026;94(4):1331\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2025.12.092.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1849_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.36849\/jdd.8926","volume":"24","author":"N Gupta","year":"2025","unstructured":"Gupta N, Zafar K, Patel P, et al. Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa: a multicenter TriNetX cohort study. J Drugs Dermatol. 2025;24(9):869\u201374. https:\/\/doi.org\/10.36849\/jdd.8926.","journal-title":"J Drugs Dermatol"},{"key":"1849_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01049-8","author":"MA Visan","year":"2026","unstructured":"Visan MA, Carroll E, Ryan SL, et al. A systematic review of the clinical impact of GLP-1 receptor agonists in hidradenitis suppurativa. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01049-8.","journal-title":"Am J Clin Dermatol"},{"issue":"10476","key":"1849_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)02475-9.","journal-title":"Lancet"},{"key":"1849_CR17","unstructured":"Incyte Corporation. A phase 3, double-blind, randomized, placebo-controlled, efficacy and safety study of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05620823."},{"key":"1849_CR18","unstructured":"Incyte Corporation. A phase 3, double-blind, randomized, placebo-controlled, efficacy and safety study of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05620836."},{"key":"1849_CR19","unstructured":"AbbVie. A phase 3, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05889182."},{"key":"1849_CR20","unstructured":"Incyte Corporation. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06959225."},{"key":"1849_CR21","unstructured":"Incyte Corporation. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 27, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06958211."},{"key":"1849_CR22","unstructured":"MoonLake Immunotherapeutics AG. A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2025. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06411379."},{"key":"1849_CR23","unstructured":"MoonLake Immunotherapeutics AG. A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2025. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06411899."},{"key":"1849_CR24","unstructured":"Boehringer Ingelheim. Randomised, double-blind, placebo-controlled, phase IIb; phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. clinicaltrials.gov; 2025. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05819398."},{"key":"1849_CR25","unstructured":"Novartis Pharmaceuticals. A randomized, double-blind, double-dummy, placebo-controlled, multicenter, phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult and adolescent patients with moderate to severe hidradenitis suppurativa (RECHARGE-2). clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06840392."},{"key":"1849_CR26","unstructured":"AbbVie. A phase 3 multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of lutikizumab in adult and adolescent subjects with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06468228."},{"key":"1849_CR27","unstructured":"Sanofi. A randomized, double-blind, placebo-controlled, dose-ranging phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 6, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07170917."},{"key":"1849_CR28","unstructured":"Zura Bio Inc. A phase 2, multi-center study consisting of a randomized, placebo-controlled period, followed by an open-label extension period to assess the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa. clinicaltrials.gov; 2026. Accessed May 27, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06993610."},{"key":"1849_CR29","unstructured":"Doyle M. Integrative transcriptomic profiling identifies a dominant macrophage-derived IL-1\u03b2\/NLRP3 inflammasome axis in hidradenitis suppurativa. In: Presented at: American Academy of Dermatology 2026 Annual Meeting; March 2026; Denver, Colorado."},{"key":"1849_CR30","unstructured":"Porter ML. Povorcitinib in patients with moderate to severe hidradenitis suppurativa: 54-week efficacy and safety results from the STOP-HS1 & STOP-HS2 phase 3 studies. In: Presented at: American Academy of Dermatology 2026 Annual Meeting; March 2026; Denver, Colorado."},{"key":"1849_CR31","unstructured":"Kimball AB. Sonelokimab in moderate-to-severe hs: long-term results through week 40 of two phase 3 trials. In: Presented at: American Academy of Dermatology 2026 Annual Meeting; March 2026; Denver, Colorado."},{"issue":"1","key":"1849_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81(1):91\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1849_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/bjd\/ljad224","volume":"189","author":"CA Maronese","year":"2023","unstructured":"Maronese CA, Ingram JR, Marzano AV. Has the time come to assess small-molecule\/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa? Br J Dermatol. 2023;189(4):467\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad224.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1849_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40257-025-00940-0","volume":"26","author":"CB Dagenet","year":"2025","unstructured":"Dagenet CB, Lee KH, Sayed C, Hsiao JL, Shi VY. Comprehensive and updated algorithm of hidradenitis suppurativa management from the experts. Am J Clin Dermatol. 2025;26(4):487\u201397. https:\/\/doi.org\/10.1007\/s40257-025-00940-0.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:20Z","timestamp":1788981680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01849-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katrina H. Lee has served as an investigator or advisory board member for Novartis, Incyte. Vivian Y. Shi is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Vivian Y. Shi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Apogee, MoonLake, Navigator Medicine, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Oruka, Takeda, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Jennifer L. Hsiao is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      . Jennifer L. Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jennifer L. Hsiao is on the board of directors for the HS Foundation, and has served as an advisor, investigator, and\/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, and UCB. The other authors, Kenan Kherallah and Claire S. Chung, have no other conflicts to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}